@article{29936,
  keywords = {leprosy, Immunoprophylaxis, Immunotherapeutic, Vaccine, Mycobacterium indicus pranii (MIP)},
  author = {Talwar G and Gupta JC and Mustafa A and Kar HK and Katoch K and Parida SK and Reddi P and Ahmed N and Saini V and Gupta S},
  title = {Development of a potent invigorator of immune responses endowed with both preventive and therapeutic properties.},
  abstract = {<p>This article reviews briefly the making of an immunoprophylactic-cum-immunotherapeutic vaccine against leprosy. The vaccine is based on cultivable, heat-killed atypical mycobacteria, whose gene sequence is now known. It has been named Mycobacterium indicus pranii. It has received the approval of the Drug Controller General of India and the US Food and Drug Administration. Besides leprosy, M. indicus pranii has found utility in the treatment of category II ("difficult to treat") tuberculosis. It also heals ugly anogenital warts. It has preventive and therapeutic action against SP2/O myelomas. It is proving to be a potent adjuvant for enhancing antibody titers of a recombinant vaccine against human chorionic gonadotropin, with the potential of preventing pregnancy without derangement of ovulation and menstrual regularity in sexually active women.</p>
},
  year = {2017},
  journal = {Biologics : targets & therapy},
  volume = {11},
  pages = {55-63},
  issn = {1177-5475},
  url = {https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5422320/pdf/btt-11-055.pdf},
  doi = {10.2147/BTT.S128308},
  language = {eng},
}